Cargando…
Design and baseline characteristics of the Xarelto Post‐Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)
BACKGROUND: The phase III Japanese Rivaroxaban Once‐Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (J‐ROCKET AF) showed that the rivaroxaban group had a lower event rate of intracranial bleeding than the wa...
Autores principales: | Ogawa, Satoshi, Minematsu, Kazuo, Ikeda, Takanori, Kitazono, Takanari, Nakagawara, Jyoji, Miyamoto, Susumu, Murakawa, Yuji, Ohashi, Yohei, Takeichi, Makiko, Okayama, Yutaka, Yamanaka, Satoshi, Inuyama, Lyo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891422/ https://www.ncbi.nlm.nih.gov/pubmed/29657592 http://dx.doi.org/10.1002/joa3.12034 |
Ejemplares similares
-
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS
por: Ikeda, Takanori, et al.
Publicado: (2021) -
Impact of three major risk factors on clinical outcomes in patients with nonvalvular atrial fibrillation receiving rivaroxaban: Sub‐analysis from the XAPASS study
por: Ikeda, Takanori, et al.
Publicado: (2022) -
Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
por: Murakawa, Yuji, et al.
Publicado: (2020) -
Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings
por: Ikeda, Takanori, et al.
Publicado: (2019) -
Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation
por: Kitazono, Takanari, et al.
Publicado: (2019)